The plan to file Lentiglobin for sickle cell disease next year gets the green light, as a patient death is deemed unrelated to treatment.
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
Roche secures a front-line liver cancer label, but rival data at Asco show that the competition isn’t resting on its laurels.
As three Asco presentations confirm the Her2-targeting agent's potency, Daiichi Sankyo and Astrazeneca lay out an ambitious development programme.
In anti-BCMA therapy Johnson & Johnson looks to have upstaged Bristol Myers Squibb again, and both companies have backups.
The Merck & Co drug looks to extend its position in a biomarker-defined colorectal cancer niche, but is it too early to declare victory?
The Merck KGaA/Pfizer drug is said to have cured 52% of women with a rare gynaecological cancer, one of whom subsequently gave birth.
With an 83% reduction in the risk of disease recurrence in early-stage lung cancer, Astrazeneca’s Tagrisso takes the top spot at Asco.
Two progressive multiple sclerosis subjects in a high-dose six-patient cohort given ATA188 have seen their disease reverse.